about
Transcription of the sarcoplasmic/endoplasmic reticulum Ca2+-ATPase type 3 gene, ATP2A3, is regulated by the calcineurin/NFAT pathway in endothelial cellsMultidrug resistance-associated protein 4 regulates cAMP-dependent signaling pathways and controls human and rat SMC proliferationMolecular targets in heart failure gene therapy: current controversies and translational perspectivesDominant negative Ras attenuates pathological ventricular remodeling in pressure overload cardiac hypertrophyExpression of sarco (endo) plasmic reticulum calcium ATPase (SERCA) system in normal mouse cardiovascular tissues, heart failure and atherosclerosisSERCA2a gene transfer enhances eNOS expression and activity in endothelial cells.Cyclic AMP compartmentation due to increased cAMP-phosphodiesterase activity in transgenic mice with a cardiac-directed expression of the human adenylyl cyclase type 8 (AC8).Alteration in temporal kinetics of Ca2+ signaling and control of growth and proliferation.Mutation of delta-sarcoglycan is associated with Ca(2+) -dependent vascular remodeling in the Syrian hamster.Role for telomerase in pulmonary hypertensionRole of sarco/endoplasmic reticulum calcium content and calcium ATPase activity in the control of cell growth and proliferation.Sarcoplasmic reticulum Ca(2+) ATPase as a therapeutic target for heart failure.Molecular targets of current and prospective heart failure therapies.Telomere Dysfunction and Cell Senescence in Chronic Lung Diseases: Therapeutic Potential.Treatment of heart failure by calcium cycling gene therapy.Extracellular Calpain/Calpastatin Balance Is Involved in the Progression of Pulmonary Hypertension.CCR5 as a treatment target in pulmonary arterial hypertension.SERCA2a controls the mode of agonist-induced intracellular Ca2+ signal, transcription factor NFAT and proliferation in human vascular smooth muscle cells.Implication of adenylyl cyclase 8 in pathological smooth muscle cell migration occurring in rat and human vascular remodelling.Augmentation of cardiac contractility with no change in L-type Ca2+ current in transgenic mice with a cardiac-directed expression of the human adenylyl cyclase type 8 (AC8).Synergistic role of protein phosphatase inhibitor 1 and sarco/endoplasmic reticulum Ca2+ -ATPase in the acquisition of the contractile phenotype of arterial smooth muscle cells.Sarco/endoplasmic reticulum Ca2+-ATPase gene transfer reduces vascular smooth muscle cell proliferation and neointima formation in the rat.New NO Donor NCX 1443: Therapeutic Effects on Pulmonary Hypertension in the SAD Mouse Model of Sickle Cell Disease.mTOR pathway activation drives lung cell senescence and emphysema.Roles for the CX3CL1/CX3CR1 and CCL2/CCR2 Chemokine Systems in Hypoxic Pulmonary Hypertension.Osteopontin, a Key Mediator Expressed by Senescent Pulmonary Vascular Cells in Pulmonary Hypertension.Benefit of SERCA2a gene transfer to vascular endothelial and smooth muscle cells: a new aspect in therapy of cardiovascular diseases.Selective Tuberous Sclerosis Complex 1 Gene Deletion in Smooth Muscle Activates Mammalian Target of Rapamycin Signaling and Induces Pulmonary Hypertension.
P50
Q24541510-AFE6613F-4883-4AEA-9044-0F0BA8AAAC08Q24641873-110D00CD-C98E-43CE-A26E-AC1C69DE3178Q28265749-51599DFB-34CD-4FF7-B2FF-F0046D2E5708Q28266103-024D8FA1-016E-446E-B8C7-48DABD2F09E7Q30370033-3FF6845B-9993-4F89-A842-03D843DBC712Q34025110-7B41F5A9-85F0-43F1-A4E3-8DCCA9EDADFDQ34218549-4812D87A-1E7A-4C6E-9A20-BF7F47FF6DC6Q35749168-215AEB5A-649F-4D13-A16E-6CCA4BB16223Q35928235-5B11E5B9-65AD-49C5-A632-B0634865B5CCQ36776314-7236E522-8F08-4EC5-A708-8639B39C9708Q37054922-C56C63B2-A07B-4D69-9C53-24813BD209C7Q37676218-EA92F022-3F7A-4F90-8615-D5958584F286Q38076688-DD172D8F-20D8-4466-AFF7-703C9C17C326Q38533808-C6AF0CBD-FC09-4184-B27D-59C43312BC09Q40199219-26238E3A-5738-4D94-AD4C-84CEE199A764Q40855297-BBBD9E29-FDE4-45C0-8A95-BB270085FEB9Q42020850-C6FB5A74-DC5B-4F2A-9070-A7B32845AA49Q42088513-95C4AC44-B070-4E6B-BDEF-B6D4A2A64073Q43043403-D78C8B99-1A22-4852-A4F6-100FF251D41CQ44122083-29F69AB2-C565-4C03-A736-09B86CC902F3Q45858131-C6F6AC81-0520-437A-AC21-8F1A1A148417Q46636022-ECD1731B-7265-45B4-957F-1125345F1BD8Q50042419-9128DDC5-8634-4A59-A1B0-50C31D636D5CQ50130565-42DCEAC3-E0AB-4554-849E-5554CB0715D8Q51167771-97F2C7B0-FE27-4B15-9569-CAD2150F831CQ51485537-AED41231-BA20-4719-A22E-FE488302997AQ51869172-7B34F8E3-786E-4E02-BDBC-259BA7D79609Q55026570-0D3E1EC8-3916-45FB-8BF4-017E0369BBC2
P50
description
onderzoeker
@nl
name
Larissa Lipskaia
@ast
Larissa Lipskaia
@en
Larissa Lipskaia
@es
Larissa Lipskaia
@nl
Larissa Lipskaia
@sl
type
label
Larissa Lipskaia
@ast
Larissa Lipskaia
@en
Larissa Lipskaia
@es
Larissa Lipskaia
@nl
Larissa Lipskaia
@sl
prefLabel
Larissa Lipskaia
@ast
Larissa Lipskaia
@en
Larissa Lipskaia
@es
Larissa Lipskaia
@nl
Larissa Lipskaia
@sl